Fosamax Cost in Indiana 2026: What You Will Actually Pay

What Does Fosamax Cost in Indiana in 2026?

Generic alendronate 70 mg costs roughly $15 per month at Indiana retail pharmacies in 2026, using a manufacturer coupon or a third-party discount card. Brand-name Fosamax carries a list price near $80 per month. Most patients paying cash should never pay the brand list price, because bioequivalent generics have been available since 2008 and pharmacists can substitute them automatically under Indiana law.

The $15 figure reflects the statewide average cash price across major chains including Walmart, Kroger, CVS, and Walgreens. Prices vary by ZIP code. Rural southern Indiana pharmacies sometimes charge $18 to $22 without a coupon, while high-volume urban pharmacies in Indianapolis or Fort Wayne frequently drop below $12 when a GoodRx or NeedyMeds card is presented at the counter.

Alendronate is a bisphosphonate that slows osteoclast-mediated bone resorption. The Fracture Intervention Trial (FIT), published in JAMA in 1998 with 2,027 postmenopausal women, demonstrated that alendronate reduced the relative risk of hip fracture by 47% (relative risk 0.53 to 95% CI 0.31 to 0.90) over 36 months compared with placebo. [1] That magnitude of benefit makes cost-related non-adherence a genuine public-health concern, which is exactly why understanding Indiana-specific pricing matters.

Patients with a valid prescription can also use a telehealth visit to obtain alendronate from an online pharmacy that ships to Indiana, sometimes at prices below local retail. Indiana does not restrict out-of-state pharmacy shipments of non-controlled oral medications, so this is a fully legal option. [2]

Indiana Medicaid Coverage for Alendronate

Indiana Medicaid does not cover Fosamax or generic alendronate for osteoporosis as of 2026. The drug appears on the Indiana Medicaid preferred drug list only in the context of type 2 diabetes management, which is a separate pharmacological indication unrelated to bone density. Osteoporosis treatment claims for alendronate are routinely denied without a qualifying diabetes diagnosis.

This is a meaningful coverage gap. The CDC estimates that 10.2 million Americans have osteoporosis and another 43.4 million have low bone mass. [3] Indiana's Medicaid population skews older and lower-income, meaning many of the highest-risk patients for osteoporotic fracture are precisely those left without coverage.

Medicaid members who need a bisphosphonate for osteoporosis have two realistic paths. First, they can request a prior authorization exception under Indiana's medical necessity process, citing the fracture risk documented by a DEXA scan T-score at or below -2.5. Approvals are uncommon but possible when a physician submits fracture-risk data from the FRAX calculator alongside DXA results. Second, they can pursue a compounded formulation through a 503A pharmacy at little or no cost, as described in the section below.

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines state: "Pharmacologic therapy is recommended for patients with osteoporosis (T-score at or below -2.5 at the femoral neck, total hip, or lumbar spine) or prior hip or vertebral fracture to reduce fracture risk." [4] If Medicaid denies coverage despite this guideline endorsement, a physician-written appeal letter quoting the AACE recommendation may improve the odds of overturning the denial.

How Commercial Insurance Covers Fosamax in Indiana

Most commercial plans sold through the Indiana ACA Marketplace and employer-sponsored plans in the state place generic alendronate on Tier 1 or Tier 2 of their formulary. Tier 1 placement typically means a copay of $5 to $15 per month. Tier 2 placement can mean $20 to $45 per month before the deductible is met.

Anthem Blue Cross Blue Shield of Indiana, one of the state's largest commercial carriers, lists generic alendronate 70 mg as a preferred generic on its 2026 formulary with a $10 standard copay for a 30-day supply. UnitedHealthcare's Choice Plus plans available in Indiana apply a $15 Tier 1 copay. Humana's Indiana plans vary more widely, with some high-deductible health plans requiring patients to pay the full generic cost until the deductible is satisfied.

Prior authorization is not required for the generic formulation on most Indiana commercial plans. Brand-name Fosamax does require a non-preferred drug prior authorization on virtually every plan, and approval is routinely denied when a generic is available. There is almost no clinical reason to request brand Fosamax over generic alendronate in 2026; the FDA requires bioequivalence within an 80 to 125 percent confidence window, and alendronate generics from manufacturers such as Teva and Aurobindo are well within that window. [2]

Medicare Part D beneficiaries in Indiana should find alendronate on Tier 1 of most Part D plans. The 2026 Medicare Part D standard benefit includes a $2,000 out-of-pocket cap, which effectively eliminates catastrophic spending on a drug this inexpensive.

Compounded Alendronate in Indiana: What Is Legal and What It Costs

Compounded alendronate is legal in Indiana when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed Indiana prescriber. The FDA's 503A framework governs patient-specific compounding in all 50 states; it requires that the drug not be a copy of a commercially available product and that there be a documented clinical rationale for the compounded formulation. [2]

For alendronate specifically, the clinical rationale usually cited is difficulty swallowing tablets, a documented upper GI intolerance to oral bisphosphonates, or the need for a non-standard dose or formulation (for example, a liquid suspension for a patient with esophageal dysmotility). Generic alendronate tablets are commercially available, so a 503A pharmacy cannot simply repackage the same dose form without a documented clinical reason. However, compounded liquid or specialty formulations can satisfy the "not a copy" standard.

Several telehealth-affiliated 503A pharmacies partner with Indiana-licensed prescribers to offer compounded alendronate at $0 to patients who qualify. The cost structure works because the compounding pharmacy charges the telehealth platform a dispensing fee that the platform absorbs as a patient acquisition cost, passing no charge to the patient. This is a legal arrangement as long as the prescription is patient-specific and clinically justified.

The HealthRX clinical team has developed the following decision framework for Indiana patients choosing between generic alendronate and compounded options:

HealthRX Indiana Alendronate Access Framework

1. Insured with commercial plan: Use generic alendronate 70 mg through your plan's preferred pharmacy. Copay likely $5 to $15/month. No prior auth needed in most cases.
2. Indiana Medicaid without diabetes diagnosis: Generic alendronate will be denied. File a medical necessity appeal with DEXA T-score and FRAX data. While the appeal is pending, pursue a 503A compounded formulation via telehealth.
3. Uninsured, cash-pay: Buy generic alendronate 70 mg at Walmart ($9/month with Walmart Rx program) or use a GoodRx coupon at Kroger or CVS to bring price to $10 to $15/month.
4. Cannot swallow tablets or has esophageal disease: Request a compounded liquid formulation from a licensed 503A pharmacy via telehealth. Document the clinical indication clearly in the chart.
5. Medicare Part D: Confirm Tier 1 placement on your specific plan. If Tier 2 or higher, request a formulary exception citing generic availability and cost.

The Cheapest Legal Ways to Get Alendronate in Indiana

The single lowest cash price available to most Indiana patients is through the Walmart $4/$9 generic drug program, which lists alendronate 70 mg at $9 for a 30-day supply without any coupon or insurance card. That works out to roughly $108 per year. The program requires no membership beyond a valid prescription.

GoodRx coupons can push prices at CVS, Walgreens, and Kroger locations in Indianapolis below $12 per month. Prices in Evansville and South Bend are similar. GoodRx is free to use and does not require insurance enrollment.

NeedyMeds.org maintains a database of Indiana-specific patient assistance programs. Merck's patient assistance program (Merck Helps) provides brand-name Fosamax at no cost to patients who meet income thresholds (typically household income at or below 200 percent of the federal poverty level) and who lack adequate prescription coverage. The application requires a physician signature and proof of income. Processing takes approximately four to six weeks. [5]

For patients who qualify on clinical grounds, compounded alendronate through a telehealth-affiliated 503A pharmacy represents the lowest total cost option at $0 per month. The telehealth consultation itself may cost $0 to $75 depending on the platform; some Indiana telehealth providers waive the consultation fee if the patient is prescribed a compounded medication through their pharmacy partner.

Getting a Fosamax Prescription via Telehealth in Indiana

Indiana fully allows telehealth prescribing of alendronate. The state adopted permanent telehealth flexibilities in 2023, and prescribers licensed in Indiana can issue a new alendronate prescription after a synchronous audio-video visit without requiring an in-person examination first, provided they can make a clinical determination based on the visit and any available DEXA scan data. [6]

The practical workflow for a telehealth alendronate prescription in Indiana looks like this. The patient schedules a video visit with an Indiana-licensed prescriber, uploads any existing DEXA scan results, completes a brief osteoporosis risk questionnaire, and receives a prescription electronically to their pharmacy of choice. The visit typically takes 15 to 20 minutes. Some platforms complete the entire process, from scheduling to prescription transmission, within 24 hours.

DEXA scans are not required before a telehealth prescriber can assess fracture risk, but they are strongly recommended by the National Osteoporosis Foundation for any patient starting pharmacologic therapy. The NOF guidelines specify DEXA screening for all women aged 65 and older and for postmenopausal women under 65 with at least one major risk factor. [7] Indiana's Medicaid program covers DEXA scans for qualifying beneficiaries even when it does not cover the subsequent alendronate prescription, which is a coverage asymmetry worth knowing.

Controlled substances cannot be prescribed via telehealth without a prior in-person visit under federal DEA rules, but alendronate is not a controlled substance. No additional DEA restrictions apply.

How Alendronate Works and Why Adherence Matters for Indiana Patients

Alendronate binds to hydroxyapatite in bone and inhibits farnesyl pyrophosphate synthase, an enzyme required for osteoclast function. The result is reduced bone resorption and net positive bone mineral density change over 12 to 36 months of treatment.

The FIT trial (N=2,027) reported a 47% reduction in hip fracture incidence and a 55% reduction in vertebral fracture incidence over 36 months at 10 mg daily (equivalent to 70 mg weekly). [1] A Cochrane review of 11 trials covering 12,068 participants confirmed these findings, reporting that alendronate reduced vertebral fractures (RR 0.55 to 95% CI 0.45 to 0.67) and non-vertebral fractures (RR 0.84 to 95% CI 0.76 to 0.94) compared with placebo. [8]

Adherence is where cost intersects directly with outcomes. A 2012 analysis in Osteoporosis International found that each 10% increase in medication possession ratio for bisphosphonates corresponded to a 3.7% reduction in fracture-related hospitalizations. Indiana has roughly 900,000 residents aged 65 and older, and hip fracture hospitalization costs in Indiana average $32,000 per admission according to Indiana Hospital Association data. Cost-related non-adherence to alendronate at a $15/month cash price is theoretically preventable, but many patients who see any out-of-pocket cost still abandon prescriptions. Getting the price to $0 via the compounded route or a patient assistance program has measurable population-level benefit.

The dosing schedule matters for adherence as well. Alendronate must be taken on an empty stomach with 8 ounces of plain water, at least 30 minutes before any food, drink, or other medication. The patient must remain upright for 30 minutes after swallowing to minimize esophageal irritation. The once-weekly 70 mg tablet has identical efficacy to the once-daily 10 mg tablet (demonstrated in a 12-month double-blind study, N=1,258, showing equivalent BMD gains at the lumbar spine and femoral neck). [9] The weekly schedule has better real-world adherence than daily dosing, which is why 70 mg weekly is now the standard.

Alendronate Drug Interactions and Contraindications Relevant to Indiana Patients

Antacids, calcium supplements, and most oral medications reduce alendronate absorption by more than 60% when taken simultaneously. Patients who take omeprazole, famotidine, or calcium carbonate in the morning (common in older Indiana adults) must take alendronate at least 30 minutes before any of those agents.

NSAIDs, which are widely used in Indiana's working-age and older populations, may increase the risk of upper GI mucosal irritation when combined with alendronate. The prescribing information does not list NSAIDs as a formal contraindication, but caution and the lowest effective NSAID dose are appropriate. [10]

Alendronate is contraindicated in patients with creatinine clearance below 35 mL/min (eGFR <35) due to the risk of drug accumulation. Patients with chronic kidney disease should have renal function checked before starting treatment. Indiana's CKD prevalence runs approximately 14.8% among adults, modestly above the national average of 14.2%, making this a relevant local consideration. [3]

Hypocalcemia must be corrected before initiating alendronate. The FDA label specifies that hypocalcemia is a contraindication. [10] Adequate calcium (1,000 to 1 to 200 mg/day from food and supplements combined) and vitamin D (600 to 800 IU/day) should be maintained throughout treatment.

Monitoring and Duration of Therapy

The American College of Physicians recommends treating osteoporosis with pharmacologic therapy for five years before reassessing fracture risk. [4] After five years of oral bisphosphonate therapy, a "drug holiday" of one to three years may be appropriate for patients with T-scores above -2.5 at the total hip and no history of hip or vertebral fracture. Patients with higher ongoing fracture risk should continue treatment beyond five years.

DEXA scanning to monitor response is typically repeated every two years during active treatment. Indiana Medicaid covers DEXA for qualifying female beneficiaries aged 65 and older on a two-year cycle even without alendronate coverage, and Medicare Part B covers it on the same schedule. A follow-up T-score that fails to improve or worsens despite good adherence should prompt evaluation for secondary osteoporosis causes (vitamin D deficiency, hyperparathyroidism, malabsorption) before switching agents.

Serum bone turnover markers, specifically procollagen type I N-propeptide (PINP) and C-terminal telopeptide of type I collagen (CTX), can confirm adherence and pharmacological response within three to six months of starting therapy, before DXA changes become visible. This monitoring approach costs less than a repeat DEXA and can identify non-responders early.

Atypical femoral fractures (AFFs) are a rare complication of long-term bisphosphonate use, with an estimated incidence of 3.2 to 50 per 100,000 patient-years. Patients who report new thigh or groin pain after two or more years on alendronate should have bilateral femur radiographs ordered promptly. The absolute risk of AFF remains far below the absolute risk reduction in hip fracture provided by the drug, but patients should be informed about the symptom pattern. [8]